RxDoctor Payments Data

Ryan Killpack, PA

Medical · Blackfoot, IDNPI 1114405396

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,126 of the $1,788 with a category attached, or 63.0%. Stryker accounts for 64.8% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2024 at $1,097 and has fallen 83.3% since, to $184 in 2025.

$1,788in general payments, 2019–2025

Across 35 payments — averaging $51.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$1K
  • Novo Nordisk$230
  • Next Science LLC$94
  • Arthrex$93
  • Intuitive Surgical$92
  • Inspire Medical Systems, Inc.$36
  • plus $86 from 4 others

What the payments were for

  • Travel & lodging$66237%
  • Food & beverage$1,12663%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,788 in reported general payments places this provider in the 80th percentile of 265 medical providers in Idaho.

See all medical providers in Idaho

Medicare billing

Part B allowed, 2024
$7,238
Medicare patients
45
Services billed
67

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide95$89,384
MounjaroTirzepatide75$76,647
WegovySemaglutide17$26,402
Topiramate111$867
Famotidine52$271
Bupropion XlBupropion Hcl27$179
Omeprazole31$137
Bupropion Hcl12$123

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$230$115,786112 claims
Lilly USA, LLCMounjaro$31$76,64775 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 265 medical providers in Idaho.

Other medical in Blackfoot

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →